other material
confidence high
sentiment positive
materiality 0.95
CalciMedica announces positive Phase 2b CARPO topline data for Auxora in acute pancreatitis
CalciMedica, Inc.
- Trial enrolled 216 patients; primary endpoint met with up to 43.6% relative risk reduction in time to solid food tolerance vs placebo in hyper-inflamed subgroup.
- Auxora showed statistically significant dose response: severe organ failure reduced by up to 61.7% in medium dose vs placebo.
- High dose patients had 0% hospital stays >21 days vs 5.7% placebo; combined high/medium dose showed 84.3% relative risk reduction.
- Auxora well-tolerated: only 1 drug-related treatment-emergent serious adverse event across all dose groups; no related deaths in high dose.
- Company plans End-of-Phase 2 meeting with FDA and intends to present additional CT data at a medical meeting later in 2024.